nodes	percent_of_prediction	percent_of_DWPC	metapath
Icosapent—FABP7—eye—Graves' disease	0.0608	0.0845	CbGeAlD
Icosapent—FABP7—connective tissue—Graves' disease	0.0586	0.0814	CbGeAlD
Icosapent—FADS1—eye—Graves' disease	0.0552	0.0767	CbGeAlD
Icosapent—ACSL4—eye—Graves' disease	0.0501	0.0696	CbGeAlD
Icosapent—ACSL4—connective tissue—Graves' disease	0.0483	0.0671	CbGeAlD
Icosapent—FADS1—pituitary gland—Graves' disease	0.041	0.0569	CbGeAlD
Icosapent—FADS1—adipose tissue—Graves' disease	0.0408	0.0567	CbGeAlD
Icosapent—FABP7—thyroid gland—Graves' disease	0.0389	0.0541	CbGeAlD
Icosapent—ACSL4—pituitary gland—Graves' disease	0.0372	0.0517	CbGeAlD
Icosapent—ACSL4—adipose tissue—Graves' disease	0.037	0.0515	CbGeAlD
Icosapent—PPARD—adipose tissue—Graves' disease	0.0356	0.0494	CbGeAlD
Icosapent—FADS1—thyroid gland—Graves' disease	0.0353	0.0491	CbGeAlD
Icosapent—ACSL4—thyroid gland—Graves' disease	0.0321	0.0445	CbGeAlD
Icosapent—PPARD—thyroid gland—Graves' disease	0.0308	0.0428	CbGeAlD
Icosapent—Arthralgia—Methimazole—Graves' disease	0.0225	0.0941	CcSEcCtD
Icosapent—Dysgeusia—Propylthiouracil—Graves' disease	0.022	0.0921	CcSEcCtD
Icosapent—PPARG—connective tissue—Graves' disease	0.0217	0.0302	CbGeAlD
Icosapent—Musculoskeletal discomfort—Methimazole—Graves' disease	0.0197	0.0822	CcSEcCtD
Icosapent—Arthralgia—Propylthiouracil—Graves' disease	0.0192	0.08	CcSEcCtD
Icosapent—Dyspepsia—Methimazole—Graves' disease	0.019	0.0794	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.0167	0.0699	CcSEcCtD
Icosapent—PPARG—adipose tissue—Graves' disease	0.0167	0.0232	CbGeAlD
Icosapent—Dyspepsia—Propylthiouracil—Graves' disease	0.0162	0.0675	CcSEcCtD
Icosapent—Pruritus—Methimazole—Graves' disease	0.0153	0.0638	CcSEcCtD
Icosapent—PPARG—thyroid gland—Graves' disease	0.0144	0.02	CbGeAlD
Icosapent—Vomiting—Methimazole—Graves' disease	0.0137	0.0574	CcSEcCtD
Icosapent—Rash—Methimazole—Graves' disease	0.0136	0.0569	CcSEcCtD
Icosapent—Dermatitis—Methimazole—Graves' disease	0.0136	0.0568	CcSEcCtD
Icosapent—Pruritus—Propylthiouracil—Graves' disease	0.013	0.0543	CcSEcCtD
Icosapent—Vomiting—Propylthiouracil—Graves' disease	0.0117	0.0488	CcSEcCtD
Icosapent—PTGS1—connective tissue—Graves' disease	0.0116	0.0161	CbGeAlD
Icosapent—Rash—Propylthiouracil—Graves' disease	0.0116	0.0484	CcSEcCtD
Icosapent—Dermatitis—Propylthiouracil—Graves' disease	0.0116	0.0483	CcSEcCtD
Icosapent—PTGS2—connective tissue—Graves' disease	0.0111	0.0154	CbGeAlD
Icosapent—PTGS1—pituitary gland—Graves' disease	0.00894	0.0124	CbGeAlD
Icosapent—PTGS1—adipose tissue—Graves' disease	0.00891	0.0124	CbGeAlD
Icosapent—PTGS2—pituitary gland—Graves' disease	0.00855	0.0119	CbGeAlD
Icosapent—PTGS2—adipose tissue—Graves' disease	0.00852	0.0118	CbGeAlD
Icosapent—PTGS1—thyroid gland—Graves' disease	0.00771	0.0107	CbGeAlD
Icosapent—FFAR1—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.00584	0.143	CbGpPWpGaD
Icosapent—TRPV1—Ion channel transport—GABRA3—Graves' disease	0.00238	0.0581	CbGpPWpGaD
Icosapent—ACSL3—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.00139	0.0339	CbGpPWpGaD
Icosapent—FADS1—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.00116	0.0284	CbGpPWpGaD
Icosapent—FFAR1—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.00106	0.026	CbGpPWpGaD
Icosapent—ACSL4—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.00105	0.0257	CbGpPWpGaD
Icosapent—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—Graves' disease	0.00101	0.0247	CbGpPWpGaD
Icosapent—PPARD—RXR and RAR heterodimerization with other nuclear receptor—TNF—Graves' disease	0.000922	0.0226	CbGpPWpGaD
Icosapent—SLC8A1—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000856	0.0209	CbGpPWpGaD
Icosapent—TRPV1—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000827	0.0202	CbGpPWpGaD
Icosapent—FFAR1—GPCR ligand binding—TSHR—Graves' disease	0.00081	0.0198	CbGpPWpGaD
Icosapent—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FASLG—Graves' disease	0.000729	0.0178	CbGpPWpGaD
Icosapent—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—Graves' disease	0.000699	0.0171	CbGpPWpGaD
Icosapent—FFAR1—Metabolism of proteins—B3GNT2—Graves' disease	0.000687	0.0168	CbGpPWpGaD
Icosapent—FFAR1—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000687	0.0168	CbGpPWpGaD
Icosapent—PTGS2—Calcium signaling in the CD4+ TCR pathway—FASLG—Graves' disease	0.000627	0.0153	CbGpPWpGaD
Icosapent—ACSL3—Metabolism—GC—Graves' disease	0.000617	0.0151	CbGpPWpGaD
Icosapent—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2RA—Graves' disease	0.000601	0.0147	CbGpPWpGaD
Icosapent—PPARD—Adipogenesis—FAS—Graves' disease	0.0006	0.0147	CbGpPWpGaD
Icosapent—PPARD—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.00059	0.0144	CbGpPWpGaD
Icosapent—PPARG—Transcription factor regulation in adipogenesis—TNF—Graves' disease	0.000576	0.0141	CbGpPWpGaD
Icosapent—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—Graves' disease	0.000561	0.0137	CbGpPWpGaD
Icosapent—FFAR1—GPCR ligand binding—CXCL10—Graves' disease	0.000523	0.0128	CbGpPWpGaD
Icosapent—FADS1—Metabolism—GC—Graves' disease	0.000517	0.0126	CbGpPWpGaD
Icosapent—PPARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—Graves' disease	0.000504	0.0123	CbGpPWpGaD
Icosapent—SLC8A1—Myometrial Relaxation and Contraction Pathways—IL1B—Graves' disease	0.0005	0.0122	CbGpPWpGaD
Icosapent—ACSL3—Metabolism—B3GNT2—Graves' disease	0.000467	0.0114	CbGpPWpGaD
Icosapent—ACSL4—Metabolism—GC—Graves' disease	0.000467	0.0114	CbGpPWpGaD
Icosapent—FFAR1—Metabolism—GC—Graves' disease	0.000467	0.0114	CbGpPWpGaD
Icosapent—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—Graves' disease	0.000461	0.0113	CbGpPWpGaD
Icosapent—FFAR1—GPCR downstream signaling—TSHR—Graves' disease	0.000458	0.0112	CbGpPWpGaD
Icosapent—PTGS1—Overview of nanoparticle effects—TNF—Graves' disease	0.000453	0.0111	CbGpPWpGaD
Icosapent—FFAR1—Signaling by GPCR—TSHR—Graves' disease	0.000416	0.0102	CbGpPWpGaD
Icosapent—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FASLG—Graves' disease	0.000405	0.00992	CbGpPWpGaD
Icosapent—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—Graves' disease	0.000397	0.0097	CbGpPWpGaD
Icosapent—FADS1—Metabolism—B3GNT2—Graves' disease	0.000392	0.00958	CbGpPWpGaD
Icosapent—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—Graves' disease	0.000389	0.00951	CbGpPWpGaD
Icosapent—PTGS2—Overview of nanoparticle effects—TNF—Graves' disease	0.00036	0.00881	CbGpPWpGaD
Icosapent—ACSL4—Metabolism—B3GNT2—Graves' disease	0.000354	0.00867	CbGpPWpGaD
Icosapent—FFAR1—Metabolism—B3GNT2—Graves' disease	0.000354	0.00867	CbGpPWpGaD
Icosapent—SLC8A1—Hemostasis—IL2RA—Graves' disease	0.00033	0.00807	CbGpPWpGaD
Icosapent—PPARG—Adipogenesis—FAS—Graves' disease	0.000327	0.00801	CbGpPWpGaD
Icosapent—PPARG—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000322	0.00788	CbGpPWpGaD
Icosapent—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—Graves' disease	0.000299	0.0073	CbGpPWpGaD
Icosapent—FFAR1—GPCR downstream signaling—CXCL10—Graves' disease	0.000296	0.00723	CbGpPWpGaD
Icosapent—PTGS1—Selenium Micronutrient Network—ICAM1—Graves' disease	0.00027	0.00661	CbGpPWpGaD
Icosapent—FFAR1—Signaling by GPCR—CXCL10—Graves' disease	0.000269	0.00657	CbGpPWpGaD
Icosapent—PPARD—Metabolism—GC—Graves' disease	0.000263	0.00643	CbGpPWpGaD
Icosapent—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—Graves' disease	0.000256	0.00627	CbGpPWpGaD
Icosapent—PTGS2—Spinal Cord Injury—CXCL10—Graves' disease	0.000256	0.00626	CbGpPWpGaD
Icosapent—PPARD—Adipogenesis—TNF—Graves' disease	0.000255	0.00623	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—TSHR—Graves' disease	0.000245	0.006	CbGpPWpGaD
Icosapent—PPARG—Circadian rythm related genes—FAS—Graves' disease	0.000231	0.00565	CbGpPWpGaD
Icosapent—PPARG—Signaling events mediated by HDAC Class I—TNF—Graves' disease	0.000228	0.00558	CbGpPWpGaD
Icosapent—FFAR1—GPCR downstream signaling—IL2RA—Graves' disease	0.000226	0.00553	CbGpPWpGaD
Icosapent—PTGS1—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000226	0.00552	CbGpPWpGaD
Icosapent—PTGS2—Selenium Micronutrient Network—ICAM1—Graves' disease	0.000214	0.00525	CbGpPWpGaD
Icosapent—PPARG—Transcriptional regulation of white adipocyte differentiation—TNF—Graves' disease	0.000211	0.00517	CbGpPWpGaD
Icosapent—PTGS1—Selenium Micronutrient Network—IFNG—Graves' disease	0.000206	0.00503	CbGpPWpGaD
Icosapent—FFAR1—Signaling by GPCR—IL2RA—Graves' disease	0.000205	0.00502	CbGpPWpGaD
Icosapent—PPARD—Metabolism—B3GNT2—Graves' disease	0.000199	0.00487	CbGpPWpGaD
Icosapent—PTGS1—Selenium Micronutrient Network—IL1B—Graves' disease	0.000183	0.00448	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000179	0.00438	CbGpPWpGaD
Icosapent—PTGS2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	0.000177	0.00434	CbGpPWpGaD
Icosapent—PTGS2—Spinal Cord Injury—ICAM1—Graves' disease	0.00017	0.00415	CbGpPWpGaD
Icosapent—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—Graves' disease	0.000166	0.00406	CbGpPWpGaD
Icosapent—PTGS2—C-MYB transcription factor network—CD4—Graves' disease	0.000164	0.004	CbGpPWpGaD
Icosapent—PTGS2—Selenium Micronutrient Network—IFNG—Graves' disease	0.000163	0.00399	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—CXCL10—Graves' disease	0.000159	0.00388	CbGpPWpGaD
Icosapent—PTGS2—Selenium Micronutrient Network—IL1B—Graves' disease	0.000146	0.00356	CbGpPWpGaD
Icosapent—PPARG—Metabolism—GC—Graves' disease	0.000143	0.00351	CbGpPWpGaD
Icosapent—PPARG—Adipogenesis—TNF—Graves' disease	0.000139	0.0034	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.000139	0.00339	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000134	0.00327	CbGpPWpGaD
Icosapent—PTGS1—Selenium Micronutrient Network—TNF—Graves' disease	0.000133	0.00325	CbGpPWpGaD
Icosapent—PTGS2—Spinal Cord Injury—IFNG—Graves' disease	0.000129	0.00316	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—IL2RA—Graves' disease	0.000121	0.00297	CbGpPWpGaD
Icosapent—PTGS2—Spinal Cord Injury—IL1B—Graves' disease	0.000115	0.00282	CbGpPWpGaD
Icosapent—PPARG—Metabolism—B3GNT2—Graves' disease	0.000109	0.00266	CbGpPWpGaD
Icosapent—PTGS2—Selenium Micronutrient Network—TNF—Graves' disease	0.000106	0.00258	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—GC—Graves' disease	0.0001	0.00246	CbGpPWpGaD
Icosapent—PTGS2—Spinal Cord Injury—TNF—Graves' disease	8.35e-05	0.00204	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—GC—Graves' disease	7.98e-05	0.00195	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—B3GNT2—Graves' disease	7.62e-05	0.00186	CbGpPWpGaD
Icosapent—PTGS2—Disease—B3GNT2—Graves' disease	7.22e-05	0.00177	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—B3GNT2—Graves' disease	6.05e-05	0.00148	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	5.68e-05	0.00139	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—TNF—Graves' disease	4.78e-05	0.00117	CbGpPWpGaD
Icosapent—PTGS2—Disease—HLA-A—Graves' disease	2.92e-05	0.000715	CbGpPWpGaD
Icosapent—PTGS2—Disease—CD4—Graves' disease	1.88e-05	0.00046	CbGpPWpGaD
